GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » EBITDA

SCPX (Scorpius Holdings) EBITDA : $-22.84 Mil (TTM As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings EBITDA?

Scorpius Holdings's EBITDA for the three months ended in Sep. 2024 was $-8.58 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-22.84 Mil.

During the past 3 years, the average EBITDA Growth Rate was -11.40% per year. During the past 5 years, the average EBITDA Growth Rate was -17.70% per year. During the past 10 years, the average EBITDA Growth Rate was -15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Scorpius Holdings was 5.90% per year. The lowest was -106.40% per year. And the median was -22.30% per year.

Scorpius Holdings's EBITDA per Share for the three months ended in Sep. 2024 was $-245.06. Its EBITDA per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-319.41.

During the past 3 years, the average EBITDA per Share Growth Rate was 5.30% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 28.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Scorpius Holdings was 59.80% per year. The lowest was 5.30% per year. And the median was 45.20% per year.


Scorpius Holdings EBITDA Historical Data

The historical data trend for Scorpius Holdings's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scorpius Holdings EBITDA Chart

Scorpius Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.16 -24.59 -30.56 -38.26 -33.99

Scorpius Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.87 -4.45 -2.60 -7.21 -8.58

Competitive Comparison of Scorpius Holdings's EBITDA

For the Biotechnology subindustry, Scorpius Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scorpius Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Scorpius Holdings's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Scorpius Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, Scorpius Holdings's EBITDA was $-33.99 Mil.

Scorpius Holdings's EBITDA for the quarter that ended in Sep. 2024 is calculated as

Scorpius Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Sep. 2024, Scorpius Holdings's EBITDA was $-8.58 Mil.

EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Scorpius Holdings  (AMEX:SCPX) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Scorpius Holdings EBITDA Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Scorpius Holdings Business Description

Traded in Other Exchanges
N/A
Address
627 Davis Drive, Suite 400, Morrisville, NC, USA, 27560
Scorpius Holdings Inc is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities.
Executives
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf director, officer: Chief Executive Officer 3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii director C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander officer: CFO/Corp Secy 801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan director
Robert James Jakobs officer: VP Finance/Controller/Secty PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins officer: Chief Scientific Officer 15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar officer: VP of Finance and Controller C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov director 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech officer: Chief Financial Officer C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber officer: Vice President of Research 100 EUROPA DRIVE, CHAPEL HILL NC 27517